Background: Hybrid therapies use intermittent hemodialysis (IHD) machines adapted to provide prolonged intermittent or continuous renal replacement therapy in the intensive care unit (ICU). Despite the low cost, hybrid therapy use is limited warranting a novel approach. Methods: The literature was reviewed for limitations of hybrid protocols, use of regional citrate anticoagulation (RCA) on hybrid systems and sensors for IHD and hybrid therapy. The novel hybrid program in the authors’ institution is presented as a plausible future direction for the modality. Results: Hybrid therapies are limited by access flow and clotting alarms. Technology limitations render many IHD sensors inoperable at low dialysate flow. A synergy with RCA allows a novel, safe approach with low blood flows and high dialysate flows with alarm- and clotting-free operation and all commercial IHD sensors functional. Conclusion: The low cost, ease of use, safety and efficacy of hybrid therapy with near-automated RCA may lead to rapid expansion of this form of ICU renal support.

1.
Marshall MR, Golper TA: Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial 2011;24:142–148.
2.
Ahmed Z, Gilibert S, Krevolin L: Cost analysis of continuous renal replacement and extended hemodialysis. Dial Transplant 2009;38:500–503.
3.
Berbece AN, Richardson RM: Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int 2006;70:963–968.
4.
Marshall MR, Creamer JM, Foster M, Ma TM, Mann SL, Fiaccadori E, Maggiore U, Richards B, Wilson VL, Williams AB, Rankin AP: Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011;26:2169–2175.
5.
Rabindranath K, Adams J, Macleod AM, Muirhead N: Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007;3:CD003773.
6.
Overberger P, Pesacreta M, Palevsky PM: Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2007;2:623–630.
7.
Ricci Z, Ronco C, D’Amico G, De Felice R, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, Dan M, Piccinni P: Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006;21:690–696.
8.
Schlaeper C, Amerling R, Manns M, Levin NW: High clearance continuous renal replacement therapy with a modified dialysis machine. Kidney Int Suppl 1999;72:S20–S23.
9.
Messer J, Mulcahy B, Fissell WH: Middle-molecule clearance in CRRT: in vitro convection, diffusion and dialyzer area. ASAIO J 2009;55:224–226.
10.
Fiore GB, Guadagni G, Lupi A, Ricci Z, Ronco C: A new semiempirical mathematical model for prediction of internal filtration in hollow fiber hemodialyzers. Blood Purif 2006;24:555–568.
11.
Yamamoto K, Matsukawa H, Yakushiji T, Fukuda M, Hiyoshi T, Sakai K: Technical evaluation of dialysate flow in a newly designed dialyzer. ASAIO J 2007;53:36–40.
12.
Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM: Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011;39:560–570.
13.
Roberts JA, Mehta RL, Lipman J: Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing? Crit Care Med 2011;39:602–603.
14.
Ronco C, Ricci Z, Bellomo R, Baldwin I, Kellum J: Management of fluid balance in CRRT: a technical approach. Int J Artif Organs 2005;28:765–776.
15.
Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P: Haemodialysis with on-line monitoring equipment: tools or toys? Nephrol Dial Transplant 2005;20:22–33.
16.
Polaschegg HD: Hemodialysis machine technology: a global overview. Expert Rev Med Devices 2010;7:793–810.
17.
Gotch FA, Panlilio FM, Buyaki RA, Wang EX, Folden TI, Levin NW: Mechanisms determining the ratio of conductivity clearance to urea clearance. Kidney Int Suppl 2004;89:S3–S24.
18.
Section 5: dialysis interventions for treatment of AKI. Kidney Int Suppl 2012;2:S89–S115.
19.
Clark JA, Schulman G, Golper TA: Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008;3:736–742.
20.
Finkel KW, Foringer JR: Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients. Ren Fail 2005;27:541–545.
21.
Szamosfalvi B, Frinak S, Yee J: Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010;29:204–209.
22.
Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL, Program to Improve Care in Acute Renal Disease Study G: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009;76:422–427.
23.
Doshi M, Murray PT: Approach to intradialytic hypotension in intensive care unit patients with acute renal failure. Artif Organs 2003;27:772–780.
24.
Marx G, Reinhart K: Venous oximetry. Curr Opin Crit Care 2006;12:263–268.
25.
Multicentre study on peri- and postoperative central venous oxygen saturation in high-risk surgical patients. Crit Care 2006;10:R158.
26.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.
27.
Canaud B, Bosc JY, Leblanc M, Vaussenat F, Leray-Moragues H, Garred LJ, Mathieu-Daude JC, Mion C: On-line dialysis quantification in acutely ill patients: preliminary clinical experience with a multipurpose urea sensor monitoring device. ASAIO J 1998;44:184–190.
28.
Uhlin F, Fridolin I, Magnusson M, Lindberg LG: Dialysis dose (Kt/V) and clearance variation sensitivity using measurement of ultraviolet-absorbance (on-line), blood urea, dialysate urea and ionic dialysance. Nephrol Dial Transplant 2006;21:2225–2231.
29.
Yang Y, Szamosfalvi B, Yee J, Frinak S, Anslyn EV: Development of an online citrate/Ca2+ sensing system for dialysis. Analyst 2011;136:317–320.
30.
Myers FB, Lee LP: Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 2008;8:2015–2031.
31.
Shu F, Parks R, Maholtz J, Ash S, Antaki JF: Multimodal flow visualization and optimization of pneumatic blood pump for sorbent hemodialysis system. Artif Organs 2009;33:334–345.
32.
Buturovic-Ponikvar J, Gubensek J, Ponikvar R: Citrate anticoagulation for single-needle hemodialysis: safety and efficacy. Ther Apher Dial 2005;9:237–240.
33.
Sato K, Maekawa H, Sakurada M, Orita H, Komatsu Y: Direct hemoperfusion with polymyxin B immobilized fiber for abdominal sepsis in Europe. Surg Today 2011;41:754–760.
34.
Ding F, Song JH, Jung JY, Lou L, Wang M, Charles L, Westover A, Smith PL, Pino CJ, Buffington DA, Humes HD: A biomimetic membrane device that modulates the excessive inflammatory response to sepsis. PloS One 2011;6:e18584.
35.
Cantaluppi V, Weber V, Lauritano C, Figliolini F, Beltramo S, Biancone L, De Cal M, Cruz D, Ronco C, Segoloni GP, Tetta C, Camussi G: Protective effect of resin adsorption on septic plasma-induced tubular injury. Crit Care 2010;14:R4.
36.
Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, Praditpornsilpa K, Eiam-Ong S: Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial 2011;15:556–564.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.